Insider Selling: Aveanna Healthcare (NASDAQ:AVAH) CEO Sells 119,884 Shares of Stock

Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) CEO Jeff Shaner sold 119,884 shares of Aveanna Healthcare stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $7.65, for a total value of $917,112.60. Following the transaction, the chief executive officer directly owned 2,992,917 shares of the company’s stock, valued at approximately $22,895,815.05. This represents a 3.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Jeff Shaner also recently made the following trade(s):

• On Thursday, February 19th, Jeff Shaner sold 173,225 shares of Aveanna Healthcare stock. The shares were sold at an average price of $7.21, for a total value of $1,248,952.25.
• On Wednesday, February 18th, Jeff Shaner sold 168,800 shares of Aveanna Healthcare stock. The stock was sold at an average price of $7.38, for a total value of $1,245,744.00.
• On Friday, January 2nd, Jeff Shaner sold 29,357 shares of Aveanna Healthcare stock. The stock was sold at an average price of $7.85, for a total transaction of $230,452.45.
• On Wednesday, December 31st, Jeff Shaner sold 27,674 shares of Aveanna Healthcare stock. The shares were sold at an average price of $8.18, for a total transaction of $226,373.32.
• On Tuesday, December 30th, Jeff Shaner sold 27,929 shares of Aveanna Healthcare stock. The stock was sold at an average price of $8.36, for a total transaction of $233,486.44.

Aveanna Healthcare Price Performance

Shares of AVAH stock traded up $0.02 during trading hours on Thursday, hitting $7.42. The company’s stock had a trading volume of 3,877,110 shares, compared to its average volume of 938,081. The company has a current ratio of 1.23, a quick ratio of 1.23 and a debt-to-equity ratio of 140.39. The business has a fifty day moving average of $8.48 and a 200-day moving average of $8.44. Aveanna Healthcare Holdings Inc. has a twelve month low of $3.67 and a twelve month high of $10.32. The stock has a market cap of $1.55 billion, a price-to-earnings ratio of 20.61 and a beta of 2.06.

Hedge Funds Weigh In On Aveanna Healthcare

Hedge funds have recently made changes to their positions in the stock. AustralianSuper Pty Ltd acquired a new stake in shares of Aveanna Healthcare during the 3rd quarter worth $15,743,000. Vanguard Group Inc. grew its position in Aveanna Healthcare by 38.0% during the fourth quarter. Vanguard Group Inc. now owns 5,577,010 shares of the company’s stock valued at $45,564,000 after acquiring an additional 1,535,351 shares during the period. Millennium Management LLC increased its stake in Aveanna Healthcare by 1,007.1% during the fourth quarter. Millennium Management LLC now owns 1,114,717 shares of the company’s stock worth $9,107,000 after acquiring an additional 1,014,030 shares during the last quarter. Nuveen LLC raised its holdings in shares of Aveanna Healthcare by 135.9% in the 4th quarter. Nuveen LLC now owns 1,571,308 shares of the company’s stock worth $12,838,000 after purchasing an additional 905,316 shares during the period. Finally, Hillsdale Investment Management Inc. acquired a new position in shares of Aveanna Healthcare in the 3rd quarter valued at about $7,922,000. Institutional investors and hedge funds own 87.96% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the company. Barclays upped their price objective on Aveanna Healthcare from $9.00 to $11.00 and gave the company an “overweight” rating in a research report on Friday, January 16th. William Blair initiated coverage on shares of Aveanna Healthcare in a report on Monday, December 8th. They set an “outperform” rating for the company. Zacks Research lowered shares of Aveanna Healthcare from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 3rd. Jefferies Financial Group raised their target price on shares of Aveanna Healthcare from $11.00 to $12.50 and gave the stock a “buy” rating in a research report on Tuesday, October 28th. Finally, UBS Group boosted their price target on Aveanna Healthcare from $9.50 to $10.00 and gave the company a “neutral” rating in a report on Thursday, January 15th. Five investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $11.06.

Aveanna Healthcare Company Profile

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.